Folfox+Irinotecan+Chemort In Esophageal Cancer

Status Recruiting

Clinical Trial Summary

In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Liposomal irinotecan

Clinical Trial Description

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves the following standard of care interventions: - FOLFOX (leucovorin calcium, 5-Fluorouracil, and oxaliplatin) - Carboplatin - Paclitaxel - Radiation therapy This research study involves the following study intervention: - Liposomal irinotecan It is expected that about 40 people will take part in this research study. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The U.S. Food and Drug Administration (FDA) has not approved liposomal irinotecan for your specific disease but it has been approved for other uses. The FDA has approved FOLFOX, carboplatin, and paclitaxel as treatment options for this disease. ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Esophageal Neoplasms
Esophagogastric Cancer
Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details

NCT number	NCT04656041
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Theodore S Hong, MD
Phone	(617) 726-6050
Email	tshong1@mgh.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	June 29, 2021
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Active, not recruiting	`NCT05008783` - A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma	Phase 3
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Recruiting	`NCT03421288` - Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness	Phase 2
Completed	`NCT03196232` - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer	Phase 2
Terminated	`NCT03511222` - Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors	Phase 1
Completed	`NCT02891447` - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer	Phase 2
Completed	`NCT02864381` - Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Terminated	`NCT04032704` - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT03615326` - Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Phase 3
Completed	`NCT02830594` - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer	Phase 2
Completed	`NCT02539225` - A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT06038578` - A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer	Phase 2
Completed	`NCT04808791` - iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2
Recruiting	`NCT04581473` - Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection	Phase 1/Phase 2
Completed	`NCT00515411` - Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT06206278` - Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma	Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2